非HLA自身抗体在肾移植并发症中的新兴重要性
本文综述了非HLA自身抗体在肾移植并发症中的作用。与组成性表达于移植物内皮细胞表面的HLA不同,自身抗原通常处于隐匿状态;缺血再灌注、血管损伤和/或排斥相关的组织损伤为隐匿自身抗原的表达创造了允许条件,使自身抗体结合抗原靶点并进一步加剧血管炎症和肾功能障碍。抗perlecan/LG3抗体和抗血管紧张素II 1型受体抗体可在新发移植患者移植前检出,并预示肾移植患者长期结局不良。
要点
- 供者HLA特异性抗体参与多数实体器官移植抗体介导排斥反应。
- 非HLA自身抗体可在移植前以天然自身抗体形式产生。
- 组织损伤为隐匿自身抗原表达创造条件,自身抗体结合后加剧血管炎症和肾功能障碍。
核心结论
- 越来越多证据提示,针对隐匿抗原的自身抗体是肾功能障碍及急慢性移植物排斥的新型加速因素。
研究设计与样本
- 综述,总结非HLA自身抗体在肾移植并发症中作用的证据。
主要发现
- 供者HLA特异性抗体参与实体器官移植受者多数抗体介导排斥反应。
- 非HLA自身抗体可在移植前以天然自身抗体形式产生。
- 缺血再灌注、血管损伤和/或排斥相关组织损伤为隐匿自身抗原表达创造允许条件,使自身抗体结合抗原靶点并进一步加剧血管炎症和肾功能障碍。
- 抗perlecan/LG3抗体和抗血管紧张素II 1型受体抗体可在新发移植患者移植前检出,并预示肾移植患者长期结局不良。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibodies that are specific to organ donor HLA have been involved in the majority of cases of antibody-mediated rejection in solid organ transplant recipients. However, recent data show that production of non-HLA autoantibodies can occur before transplant in the form of natural autoantibodies. In contrast to HLAs, which are constitutively expressed on the cell surface of the allograft endothelium, autoantigens are usually cryptic. Tissue damage associated with ischemia-reperfusion, vascular injury, and/or rejection creates permissive conditions for the expression of cryptic autoantigens, allowing these autoantibodies to bind antigenic targets and further enhance vascular inflammation and renal dysfunction. Antiperlecan/LG3 antibodies and antiangiotensin II type 1 receptor antibodies have been found before transplant in patients with de novo transplants and portend negative long-term outcome in patients with renal transplants. Here, we review mounting evidence suggesting an important role for autoantibodies to cryptic antigens as novel accelerators of kidney dysfunction and acute or chronic allograft rejection.
引用
- Cardinal H, Dieudé M, Hébert MJ, et al. The Emerging Importance of Non-HLA Autoantibodies in Kidney Transplant Complications. J Am Soc Nephrol. 2016. PMID: 27798244. doi:10.1681/ASN.2016070756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。